DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,008 filers reported holding DANAHER CORPORATION in Q1 2022. The put-call ratio across all filers is 1.38 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $542,425 | -11.3% | 2,186 | -14.2% | 0.04% | -9.8% |
| Q2 2023 | $611,356 | -31.7% | 2,547 | -28.3% | 0.04% | -33.9% |
| Q1 2023 | $895,081 | -7.5% | 3,551 | -2.6% | 0.06% | -7.5% |
| Q4 2022 | $967,449 | +0.8% | 3,645 | -1.9% | 0.07% | -8.2% |
| Q3 2022 | $960,000 | -19.3% | 3,717 | -20.8% | 0.07% | -15.1% |
| Q2 2022 | $1,190,000 | -11.3% | 4,694 | +2.6% | 0.09% | +3.6% |
| Q1 2022 | $1,342,000 | -1.5% | 4,574 | +10.4% | 0.08% | -1.2% |
| Q4 2021 | $1,363,000 | +8.8% | 4,142 | -1.9% | 0.08% | +6.3% |
| Q3 2021 | $1,253,000 | +19.4% | 4,223 | +8.0% | 0.08% | +6.8% |
| Q2 2021 | $1,049,000 | +26.1% | 3,910 | +5.9% | 0.07% | +15.6% |
| Q1 2021 | $832,000 | +2.1% | 3,692 | +0.8% | 0.06% | -7.2% |
| Q4 2020 | $815,000 | +4.4% | 3,662 | +1.0% | 0.07% | -5.5% |
| Q3 2020 | $781,000 | +23.0% | 3,626 | +0.9% | 0.07% | +7.4% |
| Q2 2020 | $635,000 | +56.8% | 3,592 | +22.6% | 0.07% | +15.3% |
| Q1 2020 | $405,000 | -9.0% | 2,930 | +0.7% | 0.06% | +31.1% |
| Q4 2019 | $445,000 | +6.5% | 2,909 | +0.6% | 0.04% | -2.2% |
| Q3 2019 | $418,000 | +72.0% | 2,891 | +70.3% | 0.05% | +48.4% |
| Q2 2019 | $243,000 | -77.6% | 1,698 | -83.0% | 0.03% | -76.7% |
| Q3 2018 | $1,086,000 | +15.2% | 10,016 | +4.4% | 0.13% | +4.7% |
| Q2 2018 | $943,000 | -4.1% | 9,598 | -4.4% | 0.13% | -2.3% |
| Q1 2018 | $983,000 | +3.7% | 10,043 | -1.2% | 0.13% | +3.2% |
| Q4 2017 | $948,000 | +9.0% | 10,160 | -0.4% | 0.13% | 0.0% |
| Q3 2017 | $870,000 | -6.2% | 10,196 | -7.4% | 0.13% | -18.2% |
| Q2 2017 | $928,000 | +4.0% | 11,010 | +5.2% | 0.15% | +2.7% |
| Q1 2017 | $892,000 | +0.1% | 10,463 | -7.8% | 0.15% | +2.0% |
| Q4 2016 | $891,000 | +2.9% | 11,347 | +3.9% | 0.15% | +1.4% |
| Q3 2016 | $866,000 | -18.2% | 10,922 | +4.7% | 0.14% | -22.0% |
| Q2 2016 | $1,059,000 | +9.2% | 10,428 | +1.9% | 0.19% | +6.3% |
| Q1 2016 | $970,000 | -11.7% | 10,238 | -13.1% | 0.18% | -12.9% |
| Q4 2015 | $1,099,000 | +20.9% | 11,788 | +9.9% | 0.20% | +19.6% |
| Q3 2015 | $909,000 | +3.1% | 10,723 | +3.3% | 0.17% | +17.5% |
| Q2 2015 | $882,000 | – | 10,378 | – | 0.14% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |